News
La investigadora Cintia Folgueira, Lucense del Año 2025
Este reconocimiento pone en valor la trayectoria de Cintia Folgueira y su extraordinaria contribución científica, así como su compromiso con la divulgación y la excelencia en la investigación biomédica en Galicia.
El investigador César de la Fuente reivindica la comunicación científica “como un deber hacia la sociedad” en una nueva edición del Workshop «Cómo comunicar»
El científico insistió en que, en un mundo saturado de información y ruido, la labor de los investigadores es clave para generar confianza en la ciencia y ofrecer conocimiento riguroso y accesible al público.
El grupo GIOT – HULA recibe una donación de 9.240€ para la investigación oncológica
Oviganic Ibérica – Queserías Prado es la primera empresa de la provincia de Lugo que colabora con el equipo. Su donación ha permitido sufragar una beca formativa de un año.
Calendar
COMMON SUPPORT PLATFORMS
The platforms are research support units featured by a high strategic value, equipped by cutting edge technologies and operated by highly specialised technical staff.
CALLS
All updated information on public and private competitive calls. The most convenient and safest way to send your requests.
CAREERS
Would you like to join our team? We are always looking for people with a passion for research and propelled by insatiable curiosity to join our mission of providing a better healthcare day every day. Here you can see and apply for our current vacancies.
Research Areas
ONCOLOGY
Improvement of treatments: personalised therapy and reduction of side effects.
GENETICS AND SYSTEMS BIOLOGY
Identification of genetic biomarkers of disease susceptibility and prognosis
ENDOCRINOLOGÍA, NUTRICIÓN Y METABOLISMO
The area studies obesity from different perspectives with the participation of groups from the clinical and basic fields in a synergistic way.
NEUROSCIENCES
Search for new therapeutic targets and improvement of the clinical-therapeutic management of neurological patients, mainly stroke, Alzheimer’s, Parkinson’s disease, headaches and neurological diseases caused by prions.
CARDIOVASCULAR
The general objective of the Cardiovascular Area consists of the search for new therapeutic targets and the improvement of clinical-therapeutic management.
PLATFORMS AND METODOLOGY
The area aims at providing evidence for prioritising the management of public resources, evaluating risks and identifying opportunities for improving the health of the population. From here, prioritise structural investments and action programs.
Area Leader A001 - Oncology. Lead Researcher of the group C030 - Translational Medical Oncology
Leader Area A003 - Endocrinology, nutrition and metabolism. Leader of group C006 - Molecular endocrinology
Area Leader A004 - Neurosciences. Lead researcher of group C018 - Experimental Neurology of Parkinson's Disease
Scientific Director of the IDIS - Lead Researcher of group C012 - Metabolic Disorders
Area Leader A006 - Cardiovascular. Lead Researcher of group C016 - Cardiology
Area Leader A007 - Infectology, Inflammation and Vaccines. Lead researcher of the group C020 - Genetics, Vaccines, Infections and Paedriatics (GENVIP)
Area Leader A005 - Platforms and Methodology. Lead Researcher of group C015 - Research Methodology
Area leader A002 - Genetics and Systems Biology. Lead Researcher of the group C002 - Genetics
